Story perspectives

New CAR-T Therapy Platform Promises Rapid Production Growth

9/2/2025

Summary

Story summary

Charles River Laboratories joined the EASYGEN Consortium to develop a fully automated CAR-T cell therapy production platform within 24 hours, supported by EU funding and 18 partners across eight countries.
The global CAR T-cell therapy market is expected to grow at a 22.2% CAGR through 2030 due to increasing cancer cases and new product approvals.
Bio-Rad Laboratories is expanding its QX600 Droplet Digital PCR platform and acquired Stilla Technologies to improve molecular diagnostics.
Bio-Rad faces challenges from competition and reduced federal funding, despite strong product demand.

1 of 1

Story summary

Charles River Laboratories joined the EASYGEN Consortium to develop a fully automated CAR-T cell therapy production platform within 24 hours, supported by EU funding and 18 partners across eight countries.
The global CAR T-cell therapy market is expected to grow at a 22.2% CAGR through 2030 due to increasing cancer cases and new product approvals.
Bio-Rad Laboratories is expanding its QX600 Droplet Digital PCR platform and acquired Stilla Technologies to improve molecular diagnostics.
Bio-Rad faces challenges from competition and reduced federal funding, despite strong product demand.